Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Nautilus Biotechnology, Inc. Market Cap
Based on ratings from 5 stock analysts, the Nautilus Biotechnology, Inc. stock price is expected to increase by 68.84% in 12 months. This is calculated by using the average 12-month stock price forecast for Nautilus Biotechnology, Inc.. The lowest target is $2.25 and the highest is $5. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assignedNAUT 2 buy ratings, 3 hold ratings, and 0 sell ratings. This means that analysts expect Nautilus Biotechnology, Inc. to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NAUT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of NAUT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matthew Sykes Goldman Sachs | Sell | $1.75 | Downgrade | Dec 5, 2024 |
| Subbu Nambi Guggenheim | Buy | $6 | Initiates | Jun 27, 2024 |
| Tycho Peterson Jefferies | Hold | $3 | Assumes | Jun 3, 2024 |
| Tejas Savant Morgan Stanley | Equal-Weight | $6 | Reiterates | Aug 3, 2023 |
| Matthew Sykes Goldman Sachs | Neutral | $2 | Maintains | Aug 3, 2022 |
| Tejas Savant Morgan Stanley | Equal-Weight | $6 | Maintains | Aug 3, 2022 |
| Matthew Sykes Goldman Sachs | Neutral | $4 | Maintains | Jul 14, 2022 |
Goldman Sachs | Neutral | $5 | Maintains | Apr 13, 2022 |
Morgan Stanley | Equal-Weight | Initiates | Jan 6, 2022 | |
Cowen & Co. | Outperform | Initiates | Nov 2, 2021 | |
Goldman Sachs | Neutral | Initiates | Aug 4, 2021 | |
Jefferies | Buy | Initiates | Jul 13, 2021 |
When did it IPO
2021
Staff Count
161
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Sujal M. Patel
Market Cap
$301.4M
In 2023, NAUT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NAUT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate in the Inaugural Guggenheim Healthcare Conference, showcasing its single-molecule protein analysis platform.
Why It Matters - Nautilus Biotechnology's participation in a prominent healthcare conference may enhance visibility, attract investor interest, and signal potential growth in the biotech sector.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Dr. Mallick will be inducted into the Academy for Radiology and Biomedical Imaging Research's Council of Distinguished Investigators for his significant contributions to medical imaging.
Why It Matters - Dr. Mallick's induction signifies advancements in medical imaging, potentially enhancing healthcare technologies and impacting related investments in biotech and medical equipment sectors.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will hold its Q3 2024 earnings conference call on October 29, 2024, at 8:30 AM ET, featuring key executives and analysts.
Why It Matters - Nautilus Biotechnology's Q3 earnings call will provide insights into financial performance and future strategies, impacting stock valuation and investor sentiment.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Nautilus Biotechnology, Inc. (NASDAQ:NAUT) will hold its Q2 2024 earnings conference call on July 30, 2024, at 8:30 AM ET, featuring key company executives and analysts from major firms.
Why It Matters - Nautilus Biotechnology's upcoming earnings call could provide insights into its financial health and growth prospects, influencing stock performance and investor sentiment.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its Q2 2024 financial results on July 30, 2024, focusing on its single-molecule proteome analysis platform.
Why It Matters - Nautilus Biotechnology's Q2 financial results could impact stock performance, indicating growth potential or challenges in their innovative proteome analysis market.
Tue, 09 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Nautilus Biotechnology, Inc. will report its Q2 2024 financial results on July 30, 2024, before market open.
Why It Matters - Nautilus Biotechnology's upcoming financial results could impact stock performance, investor sentiment, and market expectations regarding its growth and innovation in protein analysis.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
